Solara Active Pharma Sciences Limited (SOLARA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Solara Active Pharma Sciences Limited (SOLARA) has a cash flow conversion efficiency ratio of 0.059x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs740.70 Million ≈ $8.01 Million USD) by net assets (Rs12.57 Billion ≈ $135.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Solara Active Pharma Sciences Limited net asset quality index to measure how much of total assets are equity-financed.
Solara Active Pharma Sciences Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Solara Active Pharma Sciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Solara Active Pharma Sciences Limited (SOLARA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Solara Active Pharma Sciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solara Active Pharma Sciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nasmed Ozel Saglik Hizmetleri Ticaret AS
IS:EGEPO
|
0.093x |
|
Kwong Lung Enterprise Co Ltd
TWO:8916
|
0.073x |
|
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
|
-0.003x |
|
Mkango Resources Ltd
V:MKA
|
3.481x |
|
Nextgreen Global Bhd
KLSE:7241
|
0.093x |
|
Hot Chili Ltd
AU:HCH
|
-0.015x |
|
ThinTech Materials Technology Co Ltd
TWO:3663
|
-0.061x |
|
Havilah Resources Ltd
AU:HAV
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Solara Active Pharma Sciences Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Solara Active Pharma Sciences Limited from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Solara Active Pharma Sciences Limited (SOLARA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs10.97 Billion ≈ $118.63 Million |
Rs2.13 Billion ≈ $23.02 Million |
0.194x | +66.91% |
| 2024-03-31 | Rs9.37 Billion ≈ $101.29 Million |
Rs1.09 Billion ≈ $11.77 Million |
0.116x | +11.78% |
| 2023-03-31 | Rs15.02 Billion ≈ $162.49 Million |
Rs1.56 Billion ≈ $16.90 Million |
0.104x | +165.95% |
| 2022-03-31 | Rs15.35 Billion ≈ $165.98 Million |
Rs-2.42 Billion ≈ $-26.17 Million |
-0.158x | -261.57% |
| 2021-03-31 | Rs15.93 Billion ≈ $172.25 Million |
Rs1.55 Billion ≈ $16.81 Million |
0.098x | -56.43% |
| 2020-03-31 | Rs10.90 Billion ≈ $117.90 Million |
Rs2.44 Billion ≈ $26.41 Million |
0.224x | +34.55% |
| 2019-03-31 | Rs9.60 Billion ≈ $103.85 Million |
Rs1.60 Billion ≈ $17.29 Million |
0.166x | +159.91% |
| 2018-03-31 | Rs7.68 Billion ≈ $83.11 Million |
Rs492.23 Million ≈ $5.32 Million |
0.064x | -100.00% |
| 2017-03-31 | Rs67.00K ≈ $724.58 |
Rs492.23 Million ≈ $5.32 Million |
7346.716x | -- |
About Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more